Rethymic (Allogenic Thymocyte-Depleted Thymus Tissue-Agdc) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rethymic. Always confirm against the full prescribing information.
100 interactions
Abatacept
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Abatacept.
Level 2 evidence
Adalimumab
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Adalimumab.
Level 2 evidence
Alclometasone
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Alclometasone.
Level 2 evidence
Aldesleukin
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Aldesleukin.
Level 2 evidence
Alemtuzumab
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Alemtuzumab.
Level 2 evidence
Amcinonide
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Amcinonide.
Level 2 evidence
Anakinra
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Anakinra.
Level 2 evidence
Anifrolumab
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Anifrolumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Level 2 evidence
Apremilast
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Apremilast.
Level 2 evidence
Arsenic trioxide
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Arsenic trioxide.
Rethymic (Allogenic Thymocyte-Depleted Thymus Tissue-Agdc) has 237 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rethymic (Allogenic Thymocyte-Depleted Thymus Tissue-Agdc) has 0 major, 0 moderate, and 237 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rethymic. Always confirm against the full prescribing information.